Cancer care innovation: The multi-cancer early detection test leaders are implementing for detection, sooner

Monday, March 13th, 2023 | 12:00 PM - 1:00 PM CT 

Cancer is predicted to remain a leading cause of death in the U.S., and cost of care for the disease could exceed $240 billion by 2030 — so it's no wonder that preventative measures and early detection are top-of-mind for leaders across the healthcare industry. To change the trajectory, many are looking to the latest innovations in oncology, including multi-cancer early detection screening. 

Join this live session to learn how Canton, Mass.-based Point32Health piloted this testing method and the positive engagement from patients.

You'll also learn about:
  • The unmet need in cancer screening, specifically for cancer types with no current screening standards
  • Techniques used in multi-cancer early detection tests to find and identify potential cancer signals
  • Current research on consumer perception + interest in multi-cancer early detection tests, as well as market research on the impact of these tests when offered as a supplemental benefit in Medicare Advantage plans


Dawn Cardeiro Headshot

Dawn Cardeiro

Director of Precision Medicine, Point32Health

Whitney Jones

Whitney Jones

Senior Medical Director, GRAIL

Joe McKenna Headshot (1)

Joe McKenna

Vice President Enterprise Partnerships, GRAIL

Prof Pic Headshot (1) (1)

Anwell Wilbekin

Senior Director, National Accounts, GRAIL